Docosahexaenoic Acid / LEF1 Cancer Research Results

DHA, Docosahexaenoic Acid: Click to Expand ⟱
Features:

Docosahexaenoic Acid (DHA) = long-chain omega-3 polyunsaturated fatty acid (22:6n-3); major structural lipid of neuronal membranes and retina; dietary sources: fatty fish (salmon, sardine), algae oils; often combined with EPA in supplements.
Primary mechanisms (conceptual rank):
1) Membrane incorporation → alters fluidity, lipid rafts, receptor signaling domains.
2) Pro-resolving lipid mediator precursor (resolvins, protectins, maresins) → inflammation resolution.
3) Mitochondrial modulation → can ↑ lipid-ROS in cancer (pro-ferroptotic bias) yet stabilize neuronal bioenergetics.
4) Synaptic function / neurogenesis support (BDNF-linked, model-dependent).
PK / bioavailability: absorbed with dietary fat; re-esterified into phospholipids; crosses BBB; brain incorporation is gradual (weeks–months); higher RBC-DHA correlates with intake.
In-vitro vs systemic exposure: many cancer studies use ≥25–100 µM free DHA; achievable plasma levels from oral dosing are typically lower and largely esterified, limiting direct comparability.
Clinical evidence status: strong cardiometabolic data; oncology evidence largely preclinical/adjunct; AD/MCI data mixed but mechanistically coherent.

Omega-3 fatty acid found in cold-water fish and some supplements.
– DHA is a major structural component of cell membranes in the brain, retina, and other tissues and plays a critical role in neural function and development.

Role in Cancer

Anti-Inflammatory Effects: – A reduction in chronic inflammation
Modulation of Cell Proliferation and Apoptosis
 –Omega-3 fatty acids appear to influence cell cycle regulation and apoptosis (programmed cell death). By enhancing apoptosis and inhibiting proliferation, these agents may limit the growth of cancer cells.
Alteration of Membrane Composition and Signaling
 –May affect processes such as angiogenesis (formation of new blood vessels), cell adhesion, and metastasis in cancer cells.
Impact on Oxidative Stress
 –Although omega-3 fatty acids are prone to oxidation, their metabolites can have antioxidant properties. Balancing oxidation and antioxidant defenses is important in preventing oxidative stress—a known contributor to DNA damage and cancer development.
Anti-Angiogenic Effects
 – Some studies have shown that EPA and DHA can inhibit angiogenesis.

Docosahexaenoic Acid (DHA) — Cancer-Relevant Pathways

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Lipid peroxidation / Ferroptosis axis ↑ (pro-ferroptotic bias; dose-dependent) ↔ / mild ↑ (buffered) P→R PUFA enrichment → lipid-ROS susceptibility DHA increases membrane PUFA content; tumors with weak GPX4 defenses more vulnerable (model-dependent).
2 ROS tone ↑ (high concentration only) ↔ P→R Oxidative stress induction Free DHA oxidation can elevate ROS in cancer; physiologic dosing less pronounced.
3 Inflammation (NF-κB / COX-2) ↓ ↓ R→G Anti-inflammatory / pro-resolving Via resolvins/protectins; may reduce tumor-promoting inflammation.
4 Membrane signaling / lipid rafts ↓ oncogenic signaling (context-dependent) Modulates receptor clustering R→G Alters RTK / Akt pathway localization Changes raft composition; can dampen EGFR/PI3K signaling (model-dependent).
5 HIF-1α / hypoxia signaling ↓ (model-dependent) ↔ G Reduced hypoxic adaptation Reported in some solid tumor models; not universal.
6 NRF2 axis ↔ / ↑ (adaptive) ↑ (protective) G Antioxidant adaptation Lipid peroxidation may secondarily activate NRF2; can limit ferroptosis in resistant tumors.
7 Ca²⁺ signaling / ER stress ↑ (high concentration only) ↔ R Stress-induced apoptosis (select models) High free DHA can perturb ER Ca²⁺ handling; typically supra-physiologic exposure.
8 Clinical Translation Constraint — — — Adjunct potential In-vitro dosing often exceeds systemic free DHA; best studied as chemo-sensitizing adjunct rather than monotherapy.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr


Docosahexaenoic Acid (DHA) — Alzheimer’s Disease–Relevant Axes

Rank Pathway / Axis Cells (neurons/glia) TSF Primary Effect Notes / Interpretation
1 Membrane fluidity / synaptic integrity ↑ G Synaptic stabilization DHA major neuronal phospholipid; supports dendritic spine density and neurotransmission.
2 Neuroinflammation resolution ↓ (pro-resolving) R→G Resolvins / protectins Promotes resolution rather than suppression of inflammation; relevant in microglial activation.
3 Mitochondrial efficiency ↑ (stabilizing) R→G Bioenergetic support Improves membrane dynamics of mitochondria; may enhance ATP coupling (model-dependent).
4 Aβ processing / amyloid burden ↓ (preclinical) G Modulates APP cleavage Animal/cell data supportive; human trials mixed, stronger in early/MCI stages.
5 BDNF / neuroplasticity ↑ (model-dependent) G Neurotrophic support Reported increase in BDNF signaling in experimental models.
6 Clinical Translation Constraint — — Stage-dependent benefit MCI/early AD may benefit; established AD shows limited cognitive reversal in RCTs; incorporation requires sustained intake.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr
LEF1, Lymphoid enhancer-binding factor 1: Click to Expand ⟱
Source:
Type:
LEF1 is essential in stem cell maintenance and organ development, especially in its role in epithelial-mesenchymal transition (EMT) by activating the transcription of hallmark EMT effectors including N-Cadherin, Vimentin, and Snail. Aberrant expression of LEF1 is implicated in tumorigenesis and cancer cell proliferation, migration, and invasion. LEF1's activity in particular cancer cell types, such as chronic lymphocytic leukemia (CLL), Burkitt lymphoma (BL), acute lymphoblastic leukemia (ALL), oral squamous cell carcinoma (OSCC), and colorectal cancer (CRC), makes it a valuable biomarker in predicting patient prognosis.

LEF1 is often considered protumorigenic due to its role in promoting cell proliferation and survival through the Wnt signaling pathway. Its activation can lead to enhanced tumor growth and metastasis.
Scientific Papers found: Click to Expand⟱
1183- DHA,    Docosahexaenoic acid inhibited the Wnt/β-catenin pathway and suppressed breast cancer cells in vitro and in vivo
- in-vitro, BC, 4T1 - in-vitro, BC, MCF-7 - in-vivo, BC, NA
TumCG↓, TumCCA↑, β-catenin/ZEB1↓, TCF↓, LEF1↓, cMyc↓, cycD1/CCND1↓, Wnt/(β-catenin)↓, TumMeta↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TCF↓, 1,   TumCG↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

LEF1↓, 1,   TumMeta↓, 1,   β-catenin/ZEB1↓, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: LEF1, Lymphoid enhancer-binding factor 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:70  Target#:384  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page